Skip to Content
You are currently on the new version of our website. Access the old version .
EpigenomesEpigenomes
  • Review
  • Open Access

7 September 2019

25 Pages

Targeting HDAC Complexes in Asthma and COPD

,
and
Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, 9713 AV Groningen, The Netherlands
*
Author to whom correspondence should be addressed.
This article belongs to the Special Issue Complex Disease Epigenetics

Abstract

Around three million patients die due to airway inflammatory diseases each year. The most notable of these diseases are asthma and chronic obstructive pulmonary disease (COPD). Therefore, new therapies are urgently needed. Promising targets are histone deacetylases (HDACs), since they regulate posttranslational protein acetylation. Over a thousand proteins are reversibly acetylated, and acetylation critically influences aberrant intracellular signaling pathways in asthma and COPD. The diverse set of selective and non-selective HDAC inhibitors used in pre-clinical models of airway inflammation show promising results, but several challenges still need to be overcome. One such challenge is the design of HDAC inhibitors with unique selectivity profiles, such as selectivity towards specific HDAC complexes. Novel strategies to disrupt HDAC complexes should be developed to validate HDACs further as targets for new anti-inflammatory pulmonary treatments.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.